Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 128.26 |
| Open | 128.01 |
| Bid | 127.00 x 1000 |
| Ask | 127.63 x 900 |
| Day's range | 127.18 - 128.48 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,204,577 |
| Market cap | 322.987B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 141.68 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.40%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
© 2024 Yahoo. All rights reserved.